Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients

• Published in: Respiration Vol. 72 Suppl 1; p. 35
• Main Authors: Langley, S J, Houghton, C M, Singh, S D
• Format: Journal Article
• Language: English
• Published: Switzerland 2005
• Subjects: Adult; Aerosol Propellants; Asthma - blood; Asthma - diagnosis; Asthma - drug therapy; Asthma - physiopathology; Blood Glucose - metabolism; Bronchial Provocation Tests; Bronchoconstrictor Agents; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - therapeutic use; Chlorofluorocarbons; Double-Blind Method; Drug Administration Schedule; Ethanolamines - administration & dosage; Ethanolamines - therapeutic use; Female; Forced Expiratory Volume - drug effects; Formoterol Fumarate; Humans; Hydrocarbons, Fluorinated; Male; Metered Dose Inhalers; Methacholine Chloride; Middle Aged; Nebulizers and Vaporizers; Potassium - blood; Powders
• ISSN: 0025-7931
• DOI: 10.1159/000083691

In this double-blind, placebo-controlled, crossover study we compared the bronchoprotective effects of formoterol 12 microg inhaled via an HFA-134a inhaler (Modulite HFA) versus a CFC and a DPI device in 38 patients with mild-to-moderate persistent asthma. All three formoterol preparations significantly increased methacholine PD20 and FEV1 and improved small airway function parameters compared with placebo (p < 0.001). No significant differences were observed between formoterol formulations. In conclusion, Modulite HFA formoterol was found to be an effective and well tolerated treatment in patients with asthma, with comparable efficacy to current formoterol preparations.